Printer Friendly

Multinational consortium reports on COVID-19 impact on cancer patients.

People with cancersickened by COVID-19 have a crude death rate of 13 percent, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published in The Lancet and simultaneously presented at ASC020 Virtual, also revealed cancer-specific factors associated with increased mortality.

The information is the first report from an ongoing international initiative by the COVID-19 and Cancer Consortium (CCC19) to track outcomes within this vulnerable population. The CCC19 registry was built and is maintained as an electronic REDCap database housed at Vanderbilt University Medical Center. The data in this first report from CCC19 was gathered from 928 patients in Spain, Canada and the United States.

"While older patients and those with major comorbid conditions are at substantially increased risk of dying from COVID-19, our early findings are encouraging news for patients without major medical conditions who receive their cancer therapy within four weeks of their infection. However, more data are needed to reliably assess individual higher risk therapies," said Nicole Kuderer, MD, with the Advanced Cancer Research Group in Seattle, one of the study's lead authors.

These early data showed no statistical association between 30-day mortality and cancer treatments, suggesting that surgery, adjuvant chemotherapy and maintenance chemotherapy could continue during the pandemic with "extreme caution."

The cancer-specific factors associated with increased mortality included having an Eastern Cooperative Oncology Group (EC0G) performance status of two or worse. EC0G is a grading scale for measuring how cancer impacts a patient's daily living abilities. A score of two designates a patient who is capable of self-care but unable to work and who is up and about more than 50 percent during waking hours. Another factor associated with increased mortality was an active cancer status, particularly progressive cancer.

The mortality risk also increased with the number of comorbidities, such as hypertension or diabetes, particularly with two or more comorbidities. As is the case with the non-cancer population, mortality increased with age. Mortality was 6 percent for cancer patients younger than 65, 11 percent for those 65-74 and 25 percent for those older than 75. Males also had a higher death rate than females, 17 percent compared to 9 percent.

CCC19 was formed to rapidly collect data as part of an effort to understand the unique effects the coronavirus has on people with cancer.

COPYRIGHT 2020 Endeavor Business Media
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Medical Laboratory Observer
Date:Jul 1, 2020
Previous Article:Fast Facts COVID-19.
Next Article:Study: Remdesivir benefits some COVID-19 patients.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters